Nuvaira is a technology company.
Nuvaira, Inc. develops innovative therapies to improve the lives of those with obstructive lung diseases. Their dNerva Lung Denervation System aims to treat overactive airway nerves.
Nuvaira has raised $147.0M across 5 funding rounds.
Nuvaira has raised $147.0M in total across 5 funding rounds.
Nuvaira is a privately held medical device company developing the dNerva Lung Denervation System, a catheter-based technology for targeted lung denervation (TLD) to treat overactive airway nerves in patients with chronic obstructive pulmonary disease (COPD) and potentially asthma[1][2][6]. It serves COPD patients—over 65 million worldwide—who suffer from exacerbations despite optimal medical therapy, aiming to preserve lung function, reduce severe exacerbations, and improve breathlessness through a one-time outpatient procedure[1][2][6]. The company has demonstrated growth momentum with over 500 patients treated, completion of the 464-patient AIRFLOW-3 pivotal trial enrollment, FDA Breakthrough Device designation, CE Mark approval in Europe, and French innovation funding for reimbursement[1][3][4].
Nuvaira was founded in 2008 by Dr. Martin Mayse and Steve Dimmer to address unmet needs in treating overactive airway nerves underlying COPD and asthma[1][5]. Early development included filing intellectual property, completing over 10 preclinical studies, 65+ animal studies treating 130+ airways, and creating the first-generation dNerva catheter via an ex-vivo program[1]. Pivotal moments followed: the first-in-human procedure in January 2012 confirmed feasibility and safety for single-procedure bilateral lung treatment; a $49 million financing round supported further trials; AIRFLOW-1 completed enrollment as a safety and dose-ranging study; AIRFLOW-2 showed reduced severe exacerbations in two-year results; and AIRFLOW-3 pivotal trial enrollment finished, backed by FDA IDE approval and Breakthrough status[1][3][4].
Nuvaira rides the trend of minimally invasive neuromodulation therapies for chronic respiratory diseases, targeting the growing COPD burden—affecting 65 million globally with high exacerbation rates despite drugs[1][6]. Timing aligns with aging populations, rising COPD prevalence, and demand for durable alternatives to inhalers or surgery; market forces include FDA/CMS support for trials (e.g., Medicare coverage for AIRFLOW-3) and European reimbursement acceleration[3][4]. It influences the ecosystem by pioneering bronchoscopic TLD, potentially expanding to asthma, validating nerve-targeting for lung diseases, and enabling faster market access via breakthrough pathways[1][2][4].
Nuvaira is poised for commercialization post-AIRFLOW-3 results, leveraging FDA Breakthrough for prioritized review and U.S. reimbursement, while building on CE Mark and French funding for European launch[3][4]. Trends like personalized respiratory interventions and value-based care will shape its path, with potential portfolio expansion (e.g., past spinal stenosis interest) amid COPD's unmet needs[3]. Its influence may evolve from trial leader to standard-of-care provider, transforming lung health preservation for millions and redefining interventional pulmonology. This positions Nuvaira as a key innovator at the intersection of medtech and chronic disease management.
Nuvaira has raised $147.0M in total across 5 funding rounds.
Nuvaira's investors include Domain Associates, Lightstone Ventures, Morgenthaler Ventures.
Nuvaira has raised $147.0M across 5 funding rounds. Most recently, it raised $79.0M Series E in February 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2019 | $79.0M Series E | Domain Associates, Lightstone Ventures, Morgenthaler Ventures | |
| Apr 1, 2014 | $42.0M Series D | Domain Associates, Lightstone Ventures, Morgenthaler Ventures | |
| Feb 1, 2013 | $10.0M Series C | Domain Associates, Lightstone Ventures, Morgenthaler Ventures | |
| Sep 1, 2012 | $11.0M Series B | Domain Associates, Lightstone Ventures, Morgenthaler Ventures | |
| Apr 1, 2011 | $5.0M Series A | Domain Associates, Morgenthaler Ventures |